ClinicalTrials.gg
Active, not recruitingNCT05869903ATTAIN-1Updated Aug 14, 2026Results posted

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase 3 interventional study of Orforglipron and Placebo in Obesity, Overweight and Overweight or Obesity, sponsored by Eli Lilly and Company. Active, not recruiting at 138 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,127
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
Largest of 22
3,127 · median 324
Started
2023
with 5 others
Phase 3
14 of 22
3 open now
Registered
5th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one has the largest enrollment, is one of 6 that started in 2023, is one of 14 in phase 3, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

03

Conditions studied

  • Obesity
  • Overweight
  • Overweight or Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a

    • ≥30.0 kilogram/square meter (kg/m²),
    • ≥27.0 kg/m² and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:

      • Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease (for example, ischemic cardiovascular disease, Functional Class I-III heart failure).
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
  • Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening.
  • Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN)2 syndrome.
  • Have had a history of chronic or acute pancreatitis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,127 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron-matching placebo, administered orally once daily (QD), for a period of 72 weeks.

    Drug: Placebo

  • Experimental
    6 mg Orforglipron

    Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 milligrams (mg) and escalated every 4 weeks until reaching a dose of 6 mg at week 8, which was then maintained up to week 72.

    Drug: Orforglipron

  • Experimental
    12 mg Orforglipron

    Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 12 mg at week 12, which was then maintained up to week 72.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron

    Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 36 mg at week 20, which was then maintained up to week 72.

    Drug: Orforglipron

Interventions

  • Administered orally.

    Also known as: LY3502970

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight (Primary Treatment Period)

    Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Change From Baseline in Waist Circumference (Primary Treatment Period)

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  2. Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  3. Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

    Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  4. Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

    Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  5. Change From Baseline in HbA1c (Primary Treatment Period)

    * Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  6. Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period)

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  7. Percent Change From Baseline in Fasting Insulin (Primary Treatment Period)

    * Fasting insulin is a blood test that measures the level of insulin in the blood after fasting. * Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  8. Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 72

  9. Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical Component and Mental Component) Scores - (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

    The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 72

  10. Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)

    Time frame: Baseline, Week 176

  11. Time to Onset of Type 2 Diabetes (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)

    Time frame: Baseline through Week 176, Baseline through Week 190

07

Results

Posted Aug 14, 2026

Participant flow

Results reported here are based on a data cutoff of 30 July 2025, corresponding to completion of the Primary Treatment Period. Final results, including the Additional Treatment Period, will be reported at the time of study completion results posting, no later than October 2028.

Participant flow — Overall Study
MilestonePlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Started949723725730
Received at least one dose of study drug948723724728
Participants with normoglycemia at randomization605465465465
Participants with prediabetes at randomization344258260265
Completed768625630639
Not completed181989591
Withdrew: Withdrawal by subject89384434
Withdrew: Lost to follow-up26141322
Withdrew: Adverse event1081316
Withdrew: Site terminated by sponsor121568
Withdrew: Protocol deviation912108
Withdrew: Lack of efficacy26210
Withdrew: Pregnancy3561
Withdrew: Other - as reported by the investigator2301
Withdrew: Physician decision3011
Withdrew: Death1110

Outcome measures

PrimaryPercent Change From Baseline in Body Weight (Primary Treatment Period)

Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight (Primary Treatment Period)
percent changePlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percent Change From Baseline in Body Weight (Primary Treatment Period)-0.87 ± 0.247-7.82 ± 0.302-9.27 ± 0.335-12.35 ± 0.364
Statistical analysis
  • Placebo vs 6 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -6.95 · 95% CI -7.71 to -6.18
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -8.40 · 95% CI -9.22 to -7.58
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -11.48 · 95% CI -12.35 to -10.61
SecondaryChange From Baseline in Waist Circumference (Primary Treatment Period)

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · centimeters
Change From Baseline in Waist Circumference (Primary Treatment Period)
centimetersPlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Waist Circumference (Primary Treatment Period)-2.09 ± 0.260-7.54 ± 0.305-9.00 ± 0.318-11.13 ± 0.318
Statistical analysis
  • Placebo vs 6 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -5.45 · 95% CI -6.23 to -4.66
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -6.90 · 95% CI -7.71 to -6.10
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -9.04 · 95% CI -9.84 to -8.23
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
millimeters of mercury (mmHg)PlaceboPooled 6 mg/12 mg/36 mg Orforglipron
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period-0.78 ± 0.404-6.14 ± 0.283
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -5.36 · 95% CI -6.32 to -4.39
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
percent changePlaceboPooled 6 mg/12 mg/36 mg Orforglipron
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period-1.41 ± 0.715-7.57 ± 0.454
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -6.25 · 95% CI -7.84 to -4.63
SecondaryPercent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
percent changePlaceboPooled 6 mg/12 mg/36 mg Orforglipron
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period-4.8 ± 1.21-16.4 ± 0.74
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -12.2 · 95% CI -14.8 to -9.5
SecondaryChange From Baseline in HbA1c (Primary Treatment Period)

* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c (Primary Treatment Period)
percentage of HbA1cPlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in HbA1c (Primary Treatment Period)-0.03 ± 0.010-0.31 ± 0.010-0.31 ± 0.010-0.38 ± 0.011
Statistical analysis
  • Placebo vs 6 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.28 · 95% CI -0.31 to -0.25
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.29 · 95% CI -0.31 to -0.26
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -0.35 · 95% CI -0.38 to -0.32
SecondaryChange From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period)

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period)
milligram per deciliter (mg/dL)Placebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period)0.28 ± 0.407-7.68 ± 0.341-8.70 ± 0.334-9.25 ± 0.378
Statistical analysis
  • Placebo vs 6 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -7.96 · 95% CI -9.01 to -6.91
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -8.98 · 95% CI -10.02 to -7.94
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -9.53 · 95% CI -10.62 to -8.44
SecondaryPercent Change From Baseline in Fasting Insulin (Primary Treatment Period)

* Fasting insulin is a blood test that measures the level of insulin in the blood after fasting. * Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with log (Actual Measurement/Baseline) = geographic region, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Fasting Insulin (Primary Treatment Period)
percent changePlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percent Change From Baseline in Fasting Insulin (Primary Treatment Period)-7.30 ± 2.211-20.64 ± 1.967-23.87 ± 2.047-32.78 ± 1.875
Statistical analysis
  • Placebo vs 6 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -14.39 · 95% CI -19.98 to -8.42
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -17.88 · 95% CI -23.46 to -11.89
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -27.49 · 95% CI -32.52 to -22.08
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with geographic region, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of Sex (female, male) and prediabetes status (yes, no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
millimeters of mercury (mmHg)PlaceboPooled 6 mg/12 mg/36 mg Orforglipron
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period-0.93 ± 0.273-2.53 ± 0.194
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -1.60 · 95% CI -2.26 to -0.94
SecondaryChange From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical Component and Mental Component) Scores - (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period

The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · T-score
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical Component and Mental Component) Scores - (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment Period
T-scorePlaceboPooled 6 mg/12 mg/36 mg Orforglipron
Physical Component Score0.76 ± 0.2322.28 ± 0.131
Mental Component Score-1.08 ± 0.244-0.65 ± 0.157
Statistical analysis
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): 1.52 · 95% CI 1.00 to 2.04
  • Placebo vs Pooled 6 mg/12 mg/36 mg Orforglipron · Mixed Models Analysis · p = 0.130 · Ls mean difference (net): 0.44 · 95% CI -0.13 to 1.00
SecondaryPercent Change From Baseline in Body Weight (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)
Time frame:
Baseline, Week 176

Results for this outcome have not been posted.

SecondaryTime to Onset of Type 2 Diabetes (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)
Time frame:
Baseline through Week 176, Baseline through Week 190

Results for this outcome have not been posted.

Adverse events

Collected over Baseline Up to Week 74. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/948 (0.1%)46/948 (4.9%)557/948 (58.8%)
6 mg Orforglipron1/723 (0.1%)40/723 (5.5%)520/723 (71.9%)
12 mg Orforglipron1/724 (0.1%)39/724 (5.4%)544/724 (75.1%)
36 mg Orforglipron0/728 (0%)28/728 (3.8%)550/728 (75.5%)
Most frequent serious events
Showing 10 of 146
Most frequent serious events
EventPlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
UreterolithiasisRenal and urinary disorders0/9483/7230/7240/728
Cholecystitis acuteHepatobiliary disorders1/9481/7231/7243/728
Testicular germ cell tumour mixedNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3410/2541/2580/264
Acute myocardial infarctionCardiac disorders2/9482/7230/7241/728
NephrolithiasisRenal and urinary disorders2/9482/7231/7240/728
Obstructive pancreatitisGastrointestinal disorders0/9480/7232/7240/728
Cholecystitis chronicHepatobiliary disorders1/9480/7232/7240/728
Dengue feverInfections and infestations0/9480/7232/7240/728
Deep vein thrombosisVascular disorders0/9480/7232/7240/728
Coronary artery diseaseCardiac disorders0/9480/7230/7242/728
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlacebo6 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
NauseaGastrointestinal disorders99/948209/723260/724245/728
ConstipationGastrointestinal disorders88/948156/723216/724185/728
VomitingGastrointestinal disorders33/94894/723155/724175/728
DiarrhoeaGastrointestinal disorders91/948152/723165/724168/728
DyspepsiaGastrointestinal disorders47/94895/723117/724103/728
Upper respiratory tract infectionInfections and infestations103/94875/72375/72464/728
HeadacheNervous system disorders71/94862/72375/72471/728
InfluenzaInfections and infestations73/94868/72358/72444/728
Abdominal distensionGastrointestinal disorders32/94852/72368/72462/728
NasopharyngitisInfections and infestations74/94855/72361/72447/728

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo6 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Mean45.1 ± 11.944.9 ± 12.145.4 ± 12.644.9 ± 11.945.1 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo6 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Female6084694674652009
Male3412542582651118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo6 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Hispanic or Latino3692732752581175
Not Hispanic or Latino5724434414671923
Unknown or Not Reported879529
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo6 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
American Indian or Alaska Native423211
Asian267202201214884
Native Hawaiian or Other Pacific Islander20103
Black or African American72686067267
White5394084053941746
More than one race54354547181
Unknown or Not Reported11810635
Region of Enrollment
Region of Enrollment(Participants)Placebo6 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Brazil273203203205884
China89696969296
India2013131662
Japan96757477322
Slovakia74565858246
South Korea2721201886
Spain95697269305
Taiwan2517182080
United States250200198198846
Baseline Body Weight
Baseline Body Weight(kilograms (kg))Placebo6 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Mean103.92 ± 22.03103.18 ± 21.65102.18 ± 21.58103.10 ± 23.15103.16 ± 22.11
08

Study locations

138 sites

Showing the first 100 of 138 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Horn DB, Shukla AP, Huang H, Twum E, Allen SE, Kis SG. Orforglipron for obesity treatment in older patients >/=65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials. Obes Pillars. 2026 Jul 14;19:100301. doi: 10.1016/j.obpill.2026.100301. eCollection 2026 Sep. PubMed 42577069 ↗
  • Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. PubMed 40960239 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jul 2025, 25 months.

Results were first posted in Aug 2026, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 25 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2023
First posted
May 22, 2023
StartActual
Jun 5, 2023
Primary completionActual
Jul 25, 2025
CompletionEst.
Oct 2027
Results first posted
Aug 14, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05869903
Responsible party
Sponsor
First posted
May 22, 2023
Start date
Jun 5, 2023
Primary completion
Jul 25, 2025
Completion
Oct 2027 (estimated)
Results posted
Aug 14, 2026
Last update
Aug 14, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion